"Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomised controlled trial"@en . . "Cerebrolysin is a compound with neurotrophic and neuroprotective activity. It is produced by enzymatic breakdown of purified brain proteins and consists of low molecular weight peptides and amino acids. Cellular and animal models of cerebral ischaemia have shown that it is a potent neuroprotective agent. We explored the safety and preliminary outcome of Cerebrolysin treatment in patients with acute stroke. Methods. Randomised, placebo-controlled, parallel group trial. Patients with acute stroke were randomised within 24 h of stroke onset to IV therapy with placebo or Cerebrolysin 50 mL/day for 21 days. Both groups received concomitant treatment with ASA 250 mg/day PO and pentoxifylline 300 mg/day IV. Clinical examinations were performed on days 1, 3, 7, 21 and 90 post baseline. Outcome measures were the Canadian Neurological Scale, the Barthel Index, the Clinical Global Impressions, the Mini-Mental State Examination, and the Syndrome Short Test. Treatment emergent adverse events, lab tests, and vital" . "14"^^ . . . "532582" . "RIV/00216208:11120/05:00001075!RIV09-MSM-11120___" . . "3"^^ . . "Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomised controlled trial" . "Cerebrolysin is a compound with neurotrophic and neuroprotective activity. It is produced by enzymatic breakdown of purified brain proteins and consists of low molecular weight peptides and amino acids. Cellular and animal models of cerebral ischaemia have shown that it is a potent neuroprotective agent. We explored the safety and preliminary outcome of Cerebrolysin treatment in patients with acute stroke. Methods. Randomised, placebo-controlled, parallel group trial. Patients with acute stroke were randomised within 24 h of stroke onset to IV therapy with placebo or Cerebrolysin 50 mL/day for 21 days. Both groups received concomitant treatment with ASA 250 mg/day PO and pentoxifylline 300 mg/day IV. Clinical examinations were performed on days 1, 3, 7, 21 and 90 post baseline. Outcome measures were the Canadian Neurological Scale, the Barthel Index, the Clinical Global Impressions, the Mini-Mental State Examination, and the Syndrome Short Test. Treatment emergent adverse events, lab tests, and vital"@en . "1"^^ . "Cerebrolysin je l\u00E1tka s neurotrofick\u00FDm a neuroprotektivn\u00EDm \u00FA\u010Dinkem. Vyr\u00E1b\u00ED se enzymatickou degradac\u00ED purifikovan\u00FDch mozkov\u00FD protein\u016F a skl\u00E1d\u00E1 se z n\u00EDzkomekul\u00E1rn\u00EDch peptid\u016F a aminokyselin. Celul\u00E1rn\u00ED a anim\u00E1ln\u00ED modely mozkov\u00E9 ischemie uk\u00E1zaly, \u017Ee m\u00E1 v\u00FDznamn\u00FD neuroprotektivn\u00ED \u00FA\u010Dinek. Provedli jsme randomizovanou, placebem kontrolovanou studii v n\u00ED\u017E nemocn\u00ED s akutn\u00EDm iktem byli randomizov\u00E1ni do 24 hodin na terapii placebem nebo Cerebrolysinem 50 ml/den po dobu 21 dn\u016F. V obou skupin\u00E1ch se pod\u00E1vala t\u00E9\u017E ASA a pentoxyphyllin. Hodnocen\u00ED provedeno kanadskou neurologickou \u0161k\u00E1lou, indexem Bartelov\u00E9 a CGI. V\u00FDsledky: 146 nemocn\u00FDch ve dvou skupin\u00E1ch, pacienti na Cerebrolysinu nem\u011Bli \u017E\u00E1dn\u00E9 signifikantn\u00ED zlep\u0161en\u00ED proti placebu ve skore CNS, BI a CGI. Signifikantn\u00ED zlep\u0161eni kognitivn\u00EDch funkc\u00ED na Cerebrolysinu bylo pozorov\u00E1no v Syndrome Short Test. Cerebrolisyn byl dob\u0159e tolerov\u00E1n a bezpe\u010Dn\u00FD."@cs . . "0300-9564" . "11120" . "AT - Rakousk\u00E1 republika" . "RIV/00216208:11120/05:00001075" . "000227148400006" . "112" . "acute stroke; neuroprotection; clinical trial; stroke therapy; Cerebrolysin"@en . "Neuroprotektivn\u00ED l\u00E9\u010Dba Cerebrolysinem u pacient\u016F s akutn\u00EDm iktem: randomisovan\u00E1 a kontrolovan\u00E1 studie"@cs . "Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomised controlled trial" . "Moessler, H." . "Ladurner, G." . "[2EE4CCC91C35]" . . "Z(MSM0021620816)" . . . "Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomised controlled trial"@en . . . "3" . "Kalvach, Pavel" . . "Neuroprotektivn\u00ED l\u00E9\u010Dba Cerebrolysinem u pacient\u016F s akutn\u00EDm iktem: randomisovan\u00E1 a kontrolovan\u00E1 studie"@cs . . . . . . "Journal of Neural Transmission" .